Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
agonist, booster, Canada, citizenship, diabetic, donor, EASD, Fatty, Glucagon, importantly, kirsten, led, lipemic, lipid, liraglutide, metastatic, Middlefield, molecular, Notably, plateaued, Road, sarcoma, shelf, stagnant, Stockholm, streptozotocin, suspected, Sweden, thereof, thiazolidinedione, underway, unresectable, weight, ZDF, Zucker
Removed:
excluded, half, immunotherapy
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view